1. The goal of this review is to familiarize the reader about the potential
involvement of the brain reward system (BRS) in symptoms of Major Depressi
ve Disorder (MDD). The authors introduce a novel approach to study the path
ophysiology of MDD that includes pharmacological probing of BRS pathways (e
.g. d-amphetamine, hydromorphone) together with an elicited and measurable
behavioral component (e.g. pleasant effects, increased energy, altered cogn
ition).
2. To this date, the major focus of MDD pathophysiology studies has been to
characterize biological differences between healthy subjects and depressed
patients such as alteration in the monoaminergic and endocrine systems. Th
e relative importance of the various biological changes has not been elucid
ated, that is, linking these with specific behavioral manifestations in MDD
have rarely been attempted.
3. One core symptom of MDD is a decreased experience of pleasure or interes
t in previously enjoyed activities (i.e. anhedonia) such as work or hobbies
, and is accompanied by decreased motivation or drive. The BRS consists of
the neural pathways involved in eliciting rewarding experiences in animals
and humans.
4. The hypothesis is that altered BRS function may be an underlying brain m
echanism of the loss of pleasure/interest experienced in MDD, and will be m
anifested through an altered response to a BRS probe. The authors have exam
ined BRS function in MDD by introducing a pharmacological probe (i.e. d-amp
hetamine/d-amph). Amphetamine is defined as a probe due to its ability to r
elease dopamine within major components of the BRS (i.e. the mesocorticolim
bic dopamine system.) In addition to the objective pharmacological effects
(e.g, altered heart rate), BRS probes like d-amph elicit reliable and measu
rable behavior, that is, the hedonic effects.
5. A review of the neurobiology of MDD, the BRS, the rationale for implicat
ing the BRS in depressive symptoms, and preliminary data, are presented in
this article.